Meibomius Bezi Disfonksiyonu ve Dislipidemi

Öz

Amaç: Dislipidemi, kan lipit profilinde, bir veya daha fazla lipid türünün anormal değerini ifade eden bir hastalıktır. Meibomius bezi disfonksiyonu (MBD), lipid bileşenlerini içeren Meibomius bezi sekresyonunun anormal durumudur. Bu çalışmamızda dislipidemi ile Meibomius bezi disfonksiyonunun şiddeti arasındaki ilişkiyi göstermeyi amaçladık.
Materyal ve Metod: Konya'da yaşayan toplam 64 katılımcı çalışmaya dahil edildi. Katılımcılar evre 0 MBD (n = 16), evre 1 MBD (n = 16), evre 2 MBD (n = 16) ve evre 3 MBD (n = 16) olarak dört gruba ayrıldı. Her hasta için meibomius bezi disfonksiyonu evresi, kan lipid profili ve Marx Çizgisi (MÇ) değerlendirildi.
Bulgular: Hastaların ortalama yaşı 48,39 (25-65 yaş aralığında) yıl olup, % 61'i (n = 39) kadın, % 39'u (n = 25) erkekti. Tüm gruplar yaş (p = 0,666) ve cinsiyet açısından benzerdi (p = 0,978). Gruplar arasında trigliserit (TG) açısından istatistiksel olarak anlamlı bir fark mevcut olup (p=0,029), artan trigliserit düzeyi ile meibomius bezi disfonksiyonunun şiddeti arasında ise güçlü bir korelasyon vardı (r=0,377). Gruplar arasında diğer kolesterol türleri açısından istatistiksel olarak anlamlı bir fark yoktu (p>0,05). Ayrıca, gruplar arasında Marx Çizgisi'nin genişliği açısından istatistiksel olarak anlamlı bir fark mevcuttu. (p <0,05).
Sonuç: Çalışmamıza göre, artmış serum total kolesterol ve trigliserit düzeyleri ile birlikte olan dislipidemi meibomius bezi disfonksiyonu ile ilişkilidir. Meibomius bezi disfonksiyonu, dislipidemi mevcudiyeti hakkında bilgi verebilir.

Anahtar Kelimeler

• Meibomius bezi disfonksiyonu,Dislipidemi,Hiperkolesterolemi,Blefarit,Marx Çizgisi

Meibomian Gland Dysfunction and Dyslipidemia

Öz

Background: Dyslipidemia is a disorder that refers to abnormal value of one or more lipid types in the blood lipid profile. Meibomian gland dysfunction (MGD) is the abnormal condition of meibomian gland secretion which contains lipid components. We aimed to show the relationship between dyslipidemia and the severity of meibomian gland dysfunction.
Materials and Methods: A total of 64 participants who live in Konya were included in the study. Participants were divided into four groups regarded as grade 0 MGD (n=16), grade 1 MGD (n=16), grade 2 MGD (n=16), and grade 3 MGD (n=16). For each patient, the grade of MGD, blood lipid profile and Marx Line (ML) were evaluated.
Results: The mean age of 48,39 (range 25-65) years, 61% (n=39) were women and 39 % (n=25) were men. All groups were similar in age (p = 0.666) and gender (p = 0.978). There was a statistically significant difference in triglyceride (TG) between groups (p=0,029) and there was a significant correlation between increasing level of triglyceride and increasing severity of stage of meibomian gland dysfunction (r=0,377). There was no statistically significant difference in other types of cholesterol between groups (p>0,05). Also, there was a statistically significant difference in width of the Marx Line between groups (p<0,05).
Conclusions: According to our study, dyslipidemia with elevated serum triglyceride and total cholesterol levels, is associated with meibomian gland dysfunction. Meibomian gland dysfunction might give the information about the presence of dyslipidemia.

Anahtar Kelimeler

• Meibomian gland dysfunction,Dyslipidemia,Hypercholesterolemia,Blepharitis,Marx Line

Kaynakça

1. 1. Bron AJ, Benjamin L, Snibson R. Meibomian gland disease: classification and grading of lid changes. Eye 1991;5:395 411.
2. 2. Nicolaides N, Kaitaranta JK, Rowdah TN, Macy JI, Boswell FM, Smith RE. Meibomian gland studies: comparison of steer and human lipids. Invest Ophthalmol Vis Sci 1981;20:522–36.
3. 3. Schein OD, Muñoz B, Tielsch JM, et al. Prevalence of dry eye among the elderly. Am J Ophthalmol 1997;124:723–8.
4. 4. Amal A. Bukhari, m.d. et al. Associations Between the Grade of Meibomian Gland Dysfunction and Dyslipidemia. Ophthal Plast Reconstr Surg 2013;29:101–103
5. 5. Macsai M. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction. Trans Am Ophthalmol Soc 2008;106:336 –356.
6. 6. Nelson JD, Shimazaki J, Benitez-del-Castillo JM, et al. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci 2011;52:1930–7.
7. 7. Butovich IA, Millar TJ, Ham BM. Understanding and analyzing meibomian lipids—a review. Curr Eye Res 2008;33:405–20.
8. 8. Wilson PW, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837.

9. 9. Tomlinson A, Bron AJ, Korb DR, et al. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci 2011;52:2006–49.
10. 10. Claire Hughes, Leona Hamilton, Michael J. Doughty, PhD, FAAO. A Quantitative Assessment of the Location and Width of Marx’s Line Along the Marginal Zone of the Human Eyelid. Optom Vis Sci 2003;80:564-72.
11. 11. Rege A, Kulkarni V, Puthran N, Khandgave T. A clinical study of subtype-based prevalence of dry eye. J Clin Diagn Res. 2013;7:2207–210.
12. 12. Shine WE, McCulley JP. Role of wax ester fatty alcohols in chronic blepharitis. Investig Ophthalmol Vis Sci 34:3515–3521.
13. 13. Shine WE, McCulley JP. Polar lipids in human meibomian gland secretions. Curr Eye Res 26:89–94.
14. 14. Dao AH, Spindle JD, Harp BA et al. Association of dyslipidemia in moderate to severe meibomian gland dysfunction. Am J Ophthalmol 150:371–375.
15. 15. Pinna A, Blasetti F, Zinellu A, Carru C, Solinas G. Meibomian gland dysfunction and hypercholesterolemia. Ophthalmology 120(12):2385–2389.
16. 16. Bettelheim FA, Brown WH, Campbell MK, Farrell SO, Torres OJ. Introduction to general, organic and biochemistry. (need to site this book properly: http://www.valorebooks.com/textbooks/introduction-to-general-organicand-biochemistry-10thth edition/9781133105084#default=buy&utm_source=Bing&utm_medium=cpc&utm_campaign=BingFTP&date=06/17/15)
17. 17. Muntner P, Colantonio LD, Cushman M, Goff DC Jr, Howard G, Howard VJ et all, Safford MM. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA 311(14):1406–1415.
18. 18. Hockley T,GemmillM. European Cholesterol GuidelinesReport. Hampshire, England: Policy Analysis Centre; 2007. Available at: http://www.policy-centre.com/downloads/European-Cholesterol- Guidelines07.pdf. Accessed March 19, 2013.
19. 19. Brahm P Guliani, Abhinav Bhalla, Mayuresh P Naik. Association of the severity of meibomian gland dysfunction with dyslipidemia in Indian population. Indian J Ophthalmol. 2018 Oct; 66(10): 1411–1416.
20. 20. Sedgwick P. Confounding in case control studies. BMJ 341:c5136.
21. 21. S. Braich . Mary K. Howard . Jorawer S. Singh Dyslipidemia and its association with meibomian gland dysfunction. International Ophthalmology August 2016, Volume 36, Issue 4, pp 469–476.
22. 22. Masahiko Yamaguchi, MD, Miki Kutsuna, MD, PHD, Toshihiko UNO, MD, PHD, Xiaodong Zheng, MD, PHD, Toshio Kodama, MD, PHD, Yuichi Ohashi, MD, PHD. Marx Line: Fluorescein Staining Line on the Inner Lid as Indicator of Meibomian Gland Function. Am J Ophthalmol 2006;141:669–675.